|
Published by: Global Markets Direct
Published: Apr. 23, 2008 - 295 Pages
Table of Contents
- 1 Table Of Contents
- 1.1 List Of Tables
- 1.2 List Of Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Definitions
- 2.2.1 Drug delivery devices
- 2.2.1.1 Needle-free Injections
- 2.2.1.2 Inhalation Systems
- 2.2.1.3 Infusion Systems
- 3 Healthcare Sector Review
- 3.1 Healthcare Expenditure
- 3.2 Healthcare Infrastructure
- 3.2.1 Healthcare Personnel Data
- 3.2.2 Healthcare Facilities Data
- 4 Drug Delivery Devices in United States.
- 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
- 4.2 Drug Delivery Devices Overall Volume (2000-2012)
- 4.3 Drug Delivery Devices Overall Company Shares (2005-2006)
- 5 Inhalation System in United States
- 5.1 Inhalation Systems Overall Revenues (2000-2012)
- 5.1.1 Metered Dose Inhalation Systems Overall Revenues (2000-2012)
- 5.1.2 Dry Powder Inhalation Systems Overall Revenues (2000-2012)
- 5.2 Inhalation Systems Overall Volume (2000-2012)
- 5.2.1 Metered Dose Inhalation Systems Overall Volume (2000-2012)
- 5.2.2 Dry Powder Inhalation Systems Overall Volume (2000-2012)
- 5.3 Inhalation Systems Average Price (2000-2012)
- 5.3.1 Metered Dose Inhalation Systems Average Price (2000-2012)
- 5.3.2 Dry Powder Inhalation Systems Average Price (2000-2012)
- 5.4 Inhalation Systems Distribution Share (2005-2006)
- 5.5 Inhalation Systems Company Share (2005-2006)
- 6 Infusion System in United States
- 6.1 Infusion Systems Overall Revenues (2000-2012)
- 6.1.1 Infusion Disposable Sets Infusion System Overall Revenues (2000-2012)
- 6.1.2 Infusion Pumps Infusion System Overall Revenue (2000-2012)
- 6.1.3 Syringe Pumps Infusion System Overall Revenue (2000-2012)
- 6.2 Infusion Systems Overall Volume (2000-2012)
- 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
- 6.2.2 Infusion Pumps Overall Volume (2000-2012)
- 6.2.3 Syringe Pumps Overall Volume (2000-2012)
- 6.3 Infusion Systems Average Price (2000-2012)
- 6.3.1 Infusion Pumps Average Price (2000-2012)
- 6.3.2 Syringe Pumps Average Price (2000-2012)
- 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
- 6.4 Infusion Systems Distribution Share (2005-2006)
- 6.5 Infusion Systems Company Share (2005-2006)
- 7 Needle Free Injections in United States
- 7.1 Needle Free Injections Overall Revenue (2000-2012)
- 7.2 Needle Free Injections Category Volume (2000-2012)
- 7.3 Needle Free Injections Average Price (2000-2012)
- 7.4 Needle Free Injections Distribution Share (2005-2006)
- 7.5 Needle Free Injections Company Share (2005-2006)
- 8 AstraZeneca PLC Company Profile
- 8.1 Company Overview
- 8.2 Business Overview
- 8.2.1 Products
- 8.2.2 History
- 8.3 Locations And Subsidiaries
- 8.4 Financial Deals Landscape
- 8.4.1 AstraZeneca Completes $6,900 Million Private Placement
- 8.4.2 AstraZeneca Acquires MedImmune
- 8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
- 8.4.4 AstraZeneca Acquires Arrow Therapeutics
- 8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
- 8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
- 8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
- 8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
- 8.4.9 Schering Signs An Agreement With AstraZeneca
- 8.4.10 AstraZeneca Signs An Agreement With Pozen
- 8.4.11 AstraZeneca Signs An Agreement With Abbott
- 8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
- 8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
- 8.4.14 AstraZeneca Acquires A Stake In Protherics
- 8.4.15 AstraZeneca Signs An Agreement With Targacept
- 8.4.16 AstraZeneca Signs An Agreement With AtheroGenics
- 8.4.17 AstraZeneca UK Signs An Agreement With Protherics
- 8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
- 8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
- 8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
- 8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
- 8.4.22 AstraZeneca Completes Private Placement Of $750 million
- 8.4.23 AstraZeneca Prices EUR750 Million Private Placement
- 8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
- 8.5 Recent Developments
- 8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- 8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
- 8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
- 8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
- 8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
- 8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
- 8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
- 8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
- 8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
- 9 GlaxoSmithKline plc Company Profile
- 9.1 Company Overview
- 9.2 Business Overview
- 9.2.1 Products
- 9.2.2 History
- 9.3 Locations And Subsidiaries
- 9.4 Financial Deals Landscape
- 9.4.1 GlaxoSmithKline Acquires CNS
- 9.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
- 9.4.3 CNS To Merge With GlaxoSmithKline
- 9.5 Recent Developments
- 9.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
- 9.5.2 Feb 07, 2008: Full-year results announcement 2007
- 9.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
- 9.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
- 9.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
- 10 3M Company Profile
- 10.1 Company Overview
- 10.2 Business Overview
- 10.2.1 Consumer and Office
- 10.2.2 Display and Graphics
- 10.2.3 Electro and Communications
- 10.2.4 Health Care
- 10.2.5 Industrial and Transportation
- 10.2.6 Safety, Security and Protection Services
- 10.2.7 Products
- 10.3 Value Chain Analysis
- 10.3.1 Manufacturing
- 10.3.2 Product Development
- 10.3.3 Sales and Marketing
- 10.4 SWOT Analysis
- 10.4.1 3M Company Strengths
- 10.4.2 3M Company Weaknesses
- 10.4.3 3M Company Opportunities
- 10.4.4 3M Company Threats
- 10.5 Financial and Operational Review
- 10.6 Locations And Subsidiaries
- 10.7 Financial Deals Landscape
- 10.7.1 3M Canada Acquires Les Entreprises Solumed
- 10.7.2 3M Acquires Bondo
- 10.7.3 3M Acquires Lingualcare
- 10.7.4 3M Acquires Abzil Industria E Comercio
- 10.7.5 3M Acquires Neo Plast
- 10.7.6 3M Acquires Assets Of DMS Chile
- 10.7.7 3M Acquires Business Of Innovative Paper Technologies
- 10.7.8 3M Acquires Powell
- 10.7.9 Gen-Probe Signs An Agreement With 3M Company
- 10.7.10 3M Acquires Acolyte Biomedica
- 10.7.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp.
- 10.7.12 3M Sells Its Pharmaceutical Business To Meda AB
- 10.7.13 3M Acquires SoftMed Systems
- 10.7.14 3M Sells its Pharmaceuticals Business to Graceway
- 10.7.15 Gen-Probe Signs An Agreement With 3M
- 10.7.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
- 10.7.17 3M Acquires Biotrace International
- 10.7.18 Ekahau Secures $16 Million In Additional Funding
- 10.7.19 3M Acquires Brontes Technologies
- 10.7.20 3M acquires Nylonge Corp
- 10.7.21 3M Signs An Agreement With ClozeX Medical
- 10.7.22 3M Acquires OMNII Oral Pharmaceuticals
- 10.7.23 3M Sells Pharmaceutical Operations In The United States To Graceway
- 10.7.24 3M Sells Pharmaceutical Business In Europe To Meda AB
- 10.7.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
- 10.7.26 3M Acquires Accuspray Application Technologies Inc.
- 10.7.27 3M to acquire Rochford Thompson Equipment
- 10.7.28 3M To Acquire Aearo Technologies From Permira
- 10.7.29 Permira To Sell Aearo Technologies To 3M
- 10.8 Recent Developments
- 10.8.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
- 10.8.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
- 10.8.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
- 10.8.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
- 10.8.5 Nov 12, 2007: 3M Declares Quarterly Dividend
- 10.8.6 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
- 10.8.7 Aug 13, 2007: 3M Declares Quarterly Dividend
- 10.8.8 May 08, 2007: 3M Declares Quarterly Dividend
- 10.8.9 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
- 11 Baxter International Company Profile
- 11.1 Company Overview
- 11.2 Business Overview
- 11.2.1 BioScience
- 11.2.2 Medication Delivery
- 11.2.3 Renal
- 11.2.4 Products
- 11.2.5 History
- 11.3 Value Chain Analysis
- 11.3.1 Manufacturing
- 11.3.2 Product Development
- 11.3.3 Sales and Marketing
- 11.4 SWOT Analysis
- 11.4.1 Baxter International Inc. Strengths
- 11.4.2 Baxter International Inc. Weaknesses
- 11.4.3 Baxter International Inc. Opportunities
- 11.4.4 Baxter International Inc. Threats
- 11.5 Financial and Operational Review
- 11.6 Locations And Subsidiaries
- 11.7 Financial Deals Landscape
- 11.7.1 Baiyunshan And Baxter Form A Joint Venture In China
- 11.7.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
- 11.7.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
- 11.7.4 B. Braun Acquires Renal Therapy Business Of Baxter
- 11.7.5 Innovata signs a license agreement with Baxter International
- 11.7.6 Kuros Biosurgery Signs An Agreement With Baxter International
- 11.7.7 Gambro Signs An Agreement With Baxter
- 11.7.8 Baxter Healthcare And Gambro Enter Into An Agreement
- 11.7.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
- 11.7.10 Baxter International And Kaketsuken Enter Into Agreement
- 11.7.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
- 11.8 Recent Developments
- 11.8.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
- 11.8.2 Dec 18, 2007: Baxter Elects CFO
- 11.8.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
- 11.8.4 Aug 01, 2007: Baxter Elects New Board Director
- 11.8.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
- 11.8.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
- 11.8.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
- 11.8.8 Nov 28, 2006: Baxter Announces Annual Dividend
- 11.8.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
- 11.9 Baxter International Inc. Pipeline Products
- 11.9.1 Next-Generation Home Hemodialysis Machine
- 11.9.1.1 Product Overview
- 11.9.1.2 Product Description
- 11.9.1.3 Product Status
- 11.9.1.4 Product Milestone
- 12 Hospira Company Profile
- 12.1 Company Overview
- 12.2 Business Overview
- 12.2.1 Injectable Pharmaceutical Custom Manufacturing Services Product Category
- 12.2.2 Other products, including critical care devices Product Category
- 12.2.3 Specialty Injectable Pharmaceuticals Product Category
- 12.2.4 Products
- 12.3 History
- 12.4 Value Chain Analysis
- 12.4.1 Manufacturing
- 12.4.2 Product Development
- 12.4.3 Sales and Marketing
- 12.5 SWOT Analysis
- 12.5.1 Hospira, Inc. Strengths
- 12.5.2 Hospira, Inc. Weaknesses
- 12.5.3 Hospira, Inc. Opportunities
- 12.5.4 Hospira, Inc. Threats
- 12.6 Financial and Operational Review
- 12.7 Locations And Subsidiaries
- 12.8 Financial Deals Landscape
- 12.8.1 Hospira Acquires Mayne Pharma
- 12.8.2 Hospira Signs An Agreement With STADA
- 12.8.3 Hospira Acquires Physiometrix
- 12.8.4 ICU Medical Acquires Salt Lake City Manufacturing Facility From Hospira
- 12.9 Recent Developments
- 12.9.1 Feb 28, 2007: Hospira Reports 2006 Results
- 12.9.2 Oct 31, 2006: Hospira Elects New Board Member
- 12.9.3 Aug 11, 2006: Hospira Appoints New CFO
- 13 Regulation System
- 13.1 Medical Equipment Approval Process
- 13.1.1 Pre-market Approval Process
- 13.1.2 Intended use and Indications for use
- 13.1.3 Predicate Device
- 13.1.4 Safe and Effective
- 13.1.5 Other Category Devices
- 13.1.6 Post-Market Approval Process
- 13.1.7 Compliance and Enforcement
- 13.1.8 Registration Fee
- 13.1.9 Approval Time
- 14 Pricing and Reimbursement
- 14.1 Government Policies
- 14.2 Private Insurance
- 14.3 Diagnosis Related Groups (DRG)
- 15 Distribution Structure
- 15.1 Distribution Structure
- 16 APPENDIX
- 16.1 Methodology
- 16.2 Currency Conversion
- 16.3 Contact Us
- 16.4 Disclaimer
AbstractUnited States Drug Delivery Devices Medical Equipment Industry Report
Summary
This report is an essential source for in-depth information and data relating to United States drug delivery devices medical equipment market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices medical equipment in United States.
Scope- The report provides sector information broken down into detailed categories and segments in country.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.
Note: Some content types may not be available in this report
Reasons to buy - Gain a strong understanding of the industry at a global level, with break downs for the country
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
